Navco Pharmaceuticals Inc.
NAV.V
TSX
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 2.10K | 1.50K | 25.20K | 2.90K | 4.30K |
| Depreciation & Amortization | -- | -- | 0.00 | -- | 500.00 |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.10K | 1.50K | 25.20K | 2.90K | 4.80K |
| Operating Income | -2.10K | -1.50K | -25.20K | -2.90K | -4.80K |
| Income Before Tax | -11.90K | -4.20K | -28.80K | -8.10K | -12.60K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -11.90K | -4.20K | -28.80K | -8.10K | -12.60K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -11.90K | -4.20K | -28.80K | -8.10K | -12.60K |
| EBIT | -2.10K | -1.50K | -25.20K | -2.90K | -4.80K |
| EBITDA | -- | -- | -19.20K | 8.30K | -4.30K |
| EPS Basic | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 57.07M | 57.07M | 57.07M | 57.07M | 57.07M |
| Average Diluted Shares Outstanding | 57.07M | 57.07M | 57.07M | 57.07M | 57.07M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |